A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become one of the standard treatment options for advanced lung cancer. However, adverse events (AEs), particularly immune–related AEs (irAEs), caused by these drugs have aroused public attention. The current network meta-analysis (NMA) aimed to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yi-Dan, Cui, Jiu-Jie, Fu, Jie, Su, Ying-Jie, Chen, Xiao-Yu, Gu, Zhi-Chun, Lin, Hou-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677695/
https://www.ncbi.nlm.nih.gov/pubmed/34925331
http://dx.doi.org/10.3389/fimmu.2021.760737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677695/
https://www.ncbi.nlm.nih.gov/pubmed/34925331
http://dx.doi.org/10.3389/fimmu.2021.760737

Ejemplares similares